Sugi Predict

Sugi Predict / Compounds / SCHEMBL5207781

SCHEMBL5207781

SCHEMBL5207781

COC(=O)c1ccccc1Nc1ccc2c(C(=O)O)nn(C3CCCCO3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ KDM4E B2RXH2 7/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ ALDH1A1 P00352 11/20 0.39
▸ HSD17B10 Q99714 6/20 0.39
▸ HPGD P15428 4/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ RECQL P46063 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ ATR Q13535 1/20 0.37
▸ TP53 P04637 2/20 0.36
▸ DGAT2 Q96PD7 1/20 0.36
▸ POLB P06746 3/20 0.36
▸ LMNA P02545 1/20 0.36
▸ PDE5A O76074 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ NR4A1 P22736 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5211276 0.95 KDM4E (0.43) MAPTALOX15KDM4ESMN1; SMN2ALDH1A1
SCHEMBL5209747 0.91 KDM4E (0.41) MAPTALOX15KDM4ESMN1; SMN2ALDH1A1
SCHEMBL6207155 0.88 ELANE (0.43) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL5210343 0.86 MAPK10 (0.39) RECQLDGAT2KMT2AMEN1BLM
SCHEMBL5208752 0.80 KDM4E (0.39) MAPTALOX15KDM4ESMN1; SMN2ALDH1A1
SCHEMBL5210148 0.80 ALDH1A1 (0.37) MAPTALOX15KDM4ESMN1; SMN2ALDH1A1
SCHEMBL5210248 0.78 KDR (0.43) SMN1; SMN2ALDH1A1DGAT2
SCHEMBL31517065 0.77 FAAH (0.37) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL29526337 0.76 ELANE (0.49) KDM4ESMN1; SMN2ATRTP53DGAT2
SCHEMBL25233771 0.75 MEN1 (0.40) KDM4ESMN1; SMN2HSD17B10NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585743-B1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER (US) 2007-05-23 — — EP disclosed
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS INC. 2006-07-20 — — US disclosed
US-7053107-B2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-05-30 — — US disclosed
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 MAPT 921/4885ALOX15 2252/4885KDM4E 2405/4885
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 MAPT 921/4885ALOX15 2252/4885KDM4E 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.